Literature DB >> 10397169

MCP-1 expression as a potential contributor to the high malignancy phenotype of murine mammary adenocarcinoma cells.

E Neumark1, R Anavi, I P Witz, A Ben-Baruch.   

Abstract

The search for mechanisms that regulate tumor progression has motivated the authors' laboratory to establish a unique murine model system, consisting of two lines of DA3 mammary adenocarcinoma cells that were derived originally from a common ancestor but differed in their malignant potential. Studies indicated that the highly malignant phenotype manifested by one of the cell lines (termed Ly-6hi DA3 cells) was associated with high expression of the Ly-6E.1 antigen. To characterize the mechanisms controlling the high malignancy phenotype expressed by Ly-6hi DA3 cells, the study was focussed on the potential contribution of tumor-derived factors to the high malignancy phenotype expressed by these cells. To this end, the expression of CC chemokines, major chemoattractants of monocytes and T cells, by the highly malignant Ly-6hi DA3 cells as compared to the low malignancy Ly-6lo DA3 cells was evaluated. The results indicate that the highly malignant cells express higher levels of factors that induce monocyte migration than the low malignancy cells. Two CC chemokines were shown to be highly produced by Ly-6hi DA3 cells, MIP-1alpha and MCP-1, of which only the latter was shown to contribute to the high migratory activity expressed by the high malignancy Ly-6hi DA3 cells. Since MCP-1 may attract monocytes to tumor sites, these findings suggest that monocyte-derived mediators, such as growth factors or angiogenic cytokines, have pro-malignancy effects that contribute to the high malignancy phenotype expressed by Ly-6hi DA3 cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397169     DOI: 10.1016/s0165-2478(99)00043-7

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  9 in total

Review 1.  Tumor-associated macrophages in breast cancer.

Authors:  Russell D Leek; Adrian L Harris
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

Review 2.  Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

Authors:  Jian Zhang; Yi Lu; Kenneth J Pienta
Journal:  J Natl Cancer Inst       Date:  2010-03-16       Impact factor: 13.506

3.  Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes.

Authors:  Terry H Wu; Karin Schreiber; Ainhoa Arina; Nikolai N Khodarev; Elena V Efimova; Donald A Rowley; Ralph R Weichselbaum; Hans Schreiber
Journal:  Cancer Immun       Date:  2011-06-30

4.  The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFα and Chemokines.

Authors:  Adit Ben-Baruch
Journal:  Cancer Microenviron       Date:  2011-12-22

5.  Hypoxia/reoxygenation induction of monocyte chemoattractant protein-1 in melanoma cells: involvement of nuclear factor-kappaB, stimulatory protein-1 transcription factors and mitogen-activated protein kinase pathways.

Authors:  Manfred Kunz; Gisela Bloss; Reinhard Gillitzer; Gerd Gross; Matthias Goebeler; Ulf R Rapp; Stephan Ludwig
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

6.  Tumour necrosis factor α enhances CCL2 and ICAM-1 expression in peripheral nerve microvascular endoneurial endothelial cells.

Authors:  Kelly A Langert; Cynthia L Von Zee; Evan B Stubbs
Journal:  ASN Neuro       Date:  2013-02-06       Impact factor: 4.146

7.  Impact of Tumor-Derived CCL2 on Macrophage Effector Function.

Authors:  M S Brault; R A Kurt
Journal:  J Biomed Biotechnol       Date:  2005

8.  Knockdown of Leptin Receptor Affects Macrophage Phenotype in the Tumor Microenvironment Inhibiting Breast Cancer Growth and Progression.

Authors:  Luca Gelsomino; Giuseppina Daniela Naimo; Rocco Malivindi; Giuseppina Augimeri; Salvatore Panza; Cinzia Giordano; Ines Barone; Daniela Bonofiglio; Loredana Mauro; Stefania Catalano; Sebastiano Andò
Journal:  Cancers (Basel)       Date:  2020-07-27       Impact factor: 6.639

9.  New therapy with ASC-J9® to suppress the prostatitis via altering the cytokine CCL2 signals.

Authors:  Shin-Jen Lin; Fu-Ju Chou; Chang-Yi Lin; Hong-Chiang Chang; Shuyuan Yeh; Chawnshang Chang
Journal:  Oncotarget       Date:  2016-10-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.